Bulk Inquiry
Limertinib
- ASK120067 - CCB120067
- Soluble in 0.1N HCl(aq), DMSO and EtOH
- MF: C29H32ClN7O2
- MW: 546.06
Description
Limertinib is a potent, selective and orally active third-generation EGFR inhibitor with IC50 values of 0.3 nM and 0.5 nM for EGFR L858R/T790M and EGFR T790M resistant mutants, respectively. Limertinib exhibited potent anti-proliferation activity in tumor cells harboring EGFR T790M (NCI-H1975) and sensitizing mutations (PC-9 and HCC827) while showed moderate or weak inhibition in cells expressing EGFR WT.
KEYWORDS: Limertinib | Supplier | EGFR inhibitor | ASK120067 | CCB120067 | ASK 120067 | ASK-120067 | CCB 120067 | CCB-120067 | CAS [1934259-00-3] | CAS [2377769-28-1] | EGF | EGFR | Inhibitor | Receptors | Non-small cell lung cancer | NSCLC | Ack1
More Information
| Parent CAS No. | 1934259-00-3 |
|---|---|
| Chemical Name | N-(5-(5-Chloro-4-(naphthalen-2-ylamino)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide |
| Short Description | EGFR inhibitor |
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1128 | Erlotinib hydrochloride |
From $77.00 |
| 1393 | Gefitinib |
From $77.00 |
| 1395 | Lapatinib ditosylate |
From $88.00 |
| 1411 | Vandetanib |
From $55.00 |
| 1433 | CI 1033 |
From $66.00 |
| 1506 | WZ 4002 |
From $77.00 |
| 1526 | Neratinib |
From $88.00 |
| 1544 | BIBW 2992 |
From $55.00 |
| 1632 | OSI 420 |
From $99.00 |
| 1653 | AEE 788 |
From $88.00 |
| 1665 | Pelitinib |
From $99.00 |
| 1760 | EGFR Inhibitor [879127-07-8] |
From $132.00 |
| 1986 | AST 1306 tosylate |
From $99.00 |
| 2031 | AIM 100 |
From $104.50 |
| 2342 | AZD9291 |
From $104.50 |
| 2563 | AZD3759 |
From $93.50 |
| 2680 | EAI045 |
From $115.50 |
| 2920 | Poziotinib |
From $104.50 |
| 2955 | NSC 228155 |
From $82.50 |
| 3040 | Abivertinib |
From $104.50 |
| 3192 | EMI48 |
From $132.00 |
| 3232 | TAK-788 |
From $77.00 |
| 3235 | Dacomitinib |
From $66.00 |
| 3802 | TAS6417 |
From Inquiry |
